ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
Dow Jones
38.239,66
0,40%
Euro vs US Dollar
1,06965
-0,04%
Bitcoin
62.802,23
-1,47%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Recursion Pharmaceuticals Inc (RXRX)

  7. Recursion Pharmaceuticals Inc (RXRX) News

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:RXRX
DatumZeitQuelleÜberschriftSymbolFirma
16/04/202414h00GlobeNewswire Inc.Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial OfficerNASDAQ:RXRXRecursion Pharmaceuticals Inc
02/04/202414h00GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
26/03/202413h00GlobeNewswire Inc.Recursion Publishes Annual Environmental, Social and Governance ReportNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/03/202409h00GlobeNewswire Inc.Recursion Announces Plans to Open New Office in LondonNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/03/202401h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
08/03/202400h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/03/202423h39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
06/03/202422h59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
05/03/202422h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/03/202420h58GlobeNewswire Inc.Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease CommunityNASDAQ:RXRXRecursion Pharmaceuticals Inc
01/03/202413h59GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferencesNASDAQ:RXRXRecursion Pharmaceuticals Inc
29/02/202414h25Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RXRXRecursion Pharmaceuticals Inc
27/02/202422h05GlobeNewswire Inc.Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
24/02/202401h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
23/02/202400h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
21/02/202423h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/02/202422h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/02/202413h59GlobeNewswire Inc.Recursion to Host Public L(earnings) Call on February 27NASDAQ:RXRXRecursion Pharmaceuticals Inc
17/02/202401h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/02/202401h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
17/02/202401h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
16/02/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202422h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202401h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202401h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202401h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202400h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/02/202422h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/02/202418h21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/02/202423h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
NASDAQ
TSLA
Tesla
COIN
ETHUSD
Ethereum
TG
ALV
Allianz
COIN
BTCUSD
Bitcoin
TG
DBK
Deutsche Bank
COIN
SOLUSD
Solana
TG
DTE
Deutsche Telekom
NASDAQ
AMZN
Amazon.com
TG
NOV
Novo Nordisk
TG
D7G
Nel ASA
NYSE
KO
Coca Cola
TG
LHA
Deutsche Lufthansa
NYSE
MRK
Merck
TG
TUI1
Tui
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten